Whole Lung Irradiation in Ewing Sarcoma with Pulmonary Metastases: Critical Appraisal of Evolution, Evidence, and Future Pathways in Precision Oncology

Read full text Summarise with VIRAT
Authors: YuanYou Yang, Lu Xie, Jie Xu, Xin Sun, Gang Ren
Cited by: 0
References: 86

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Ewing sarcoma is the second most common malignant bone tumor in children and adolescents, with a global incidence of approximately 1.5 per million. It is sensitive to both chemotherapy and radiotherapy, and is mainly treated with surgery, radiotherapy combined with multi-drug chemotherapy [ 1 , 2 ]. Approximately 25% of patients have metastases at initial diagnosis, the lungs being the most frequent site; the 5 year survival rate for patients with isolated pulmonary metastases historically ranges from 30% to 50% [ 3 , 4 , 5 ]. whole lung irradiation (WLI) has been a pivotal intervention, demonstrating clinical benefit across multiple studies [ 6 , 7 , 8 ]. Nevertheless, the integration of WLI into contemporary risk adapted and biologically guided treatment paradigms remains hotly debated. Key controversies include: (i) which patients derive sufficient benefit beyond the mere presence of lung metastases; (ii) the management of overlapping toxicities with novel systemic agents; (iii) the validation of long-term safety for modern dose sparing techniques that may trade acute high dose toxicity for chronic low dose exposure; and (iv) the absence of pediatric specific normal tissue complication probability models to guide organ at risk constraints. This article systematically examines the mechanistic basis, historical evolution, technical advancements, clinical efficacy, toxicities, and optimal timing of WLI, while critically appraising the strengths and limitations of existing data—much of which derives from non-randomized or retrospective settings with inherent selection bias. The overarching goal is to synthesize a framework that moves WLI from a largely empirical tool toward a truly personalized, evidence-based component of precision oncology. To this end, we conducted a literature search of PubMed and Embase databases up to March 2025, using keywords related to Ewing sarcoma, pulmonary metastases, and whole lung irradiation. We focused on synthesizing evidence from clinical trials, major retrospective studies, and key reviews. Consequently, this article explicitly weighs the strengths against the limitations of current data, provides a nuanced, evidence-based framework to guide personalized clinical decision making, and prioritizes the most urgent questions for future translational and clinical research.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Advanced Radiotherapy Techniques Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Current Treatment Options in Oncology
Volume
27
Issue
1
Publication date
25 March 2026
Language
EN